Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not...

Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )

Comment: POLAR gene profile can identify which patients can safely avoid...

Prof Christos Markopoulos- National and Kapodistrian University of Athens...

Longest follow-up of patients with early breast cancer shows radiotherapy does...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

ARCHERY trial: Testing AI for radiotherapy

Prof Richard Sullivan and Dr Ajay Aggarwal

ARCHERY trial: Testing AI for radiotherapy ( Prof Richard Sullivan and Dr Ajay Aggarwal )

Systemic anti-cancer performance matrix

Prof Richard Sullivan, Kari Leung and Megan McLeod

Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )

ESMO 2022: Best approaches to bladder preservation

Prof Morgan Rouprêt and Prof Nick James

ESMO 2022: Best approaches to bladder preservation ( Prof Morgan Rouprêt and Prof Nick James )

Intraoperative Radiotherapy

Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal

Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Fruquintinib provides improvement in overall survival for refractory mCRC

Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA

$Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )$

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )

More from ecancer